Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 6/20 | 0.67 |
| ▸ | NPY2R | P49146 | 7/20 | 0.66 |
| ▸ | NPY4R | P50391 | 7/20 | 0.66 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.66 |
| ▸ | NPY1R | P25929 | 5/20 | 0.66 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.63 |
| ▸ | RAMP3 | O60896 | 6/20 | 0.63 |
| ▸ | CALCR | P30988 | 6/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30481568 | 0.90 | NPY2R (0.66) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29749731 | 0.89 | APLNR (0.68) | TFPICALCR | |
| SCHEMBL30141845 | 0.88 | APLNR (0.68) | TFPICALCR | |
| SCHEMBL29700297 | 0.88 | APLNR (0.66) | TFPICALCR | |
| SCHEMBL29542556 | 0.88 | TFPI (0.70) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29625799 | 0.88 | TFPI (0.61) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL31031455 | 0.87 | KDM1A (0.65) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29625796 | 0.87 | KDM1A (0.66) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29778186 | 0.87 | AGTR2 (0.77) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29827447 | 0.86 | KEAP1 (0.62) | TFPINPY2RNPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117717614-A | Nanometer diagnosis and treatment structure with visible light and near infrared fluorescence emission and application thereof | 上海交通大学 | 2024-03-19 | — | — | CN | claimed |
| CN-120837604-A | TRPV6 targeted oncolytic peptide prodrug, preparation method and application thereof | 山东中医药大学附属医院 | 2025-10-28 | — | — | CN | disclosed |
| US-20250236666-A1 | Antibodies Against Extracellular Epitopes of Human TRPV6 Channel and their Diagnostic and Therapeutic Uses | UNIVERSITE DE LILLE (FR) | 2025-07-24 | — | — | US | disclosed |
| US-20250221936-A1 | ENGINEERED HEMICHANNELS, ENGINEERED VESICLES, AND USES THEREOF | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| EP-4529477-A1 | POROUS EXPANDING BIOCOMPATIBLE SCAFFOLDS | Danmarks Tekniske Universitet (DK) | 2025-04-02 | — | — | EP | disclosed |
| EP-4529468-A1 | FORMULATION OF API'S AND EXCIPIENT'S IN AN ICELL VIA HYDROPHOBIC ION PAIRING | Danmarks Tekniske Universitet (DK) | 2025-04-02 | — | — | EP | disclosed |
| US-12239729-B2 | TRPV3 agonists for the treatment of skin conditions | SORICIMED BIOPHARMA INC. (CA) | 2025-03-04 | — | — | US | disclosed |
| US-20250064889-A1 | TRPV6 INHIBITORS AND COMBINATION THERAPIES FOR TREATING CANCERS | SORICIMED BIOPHARMA INC (CA) | 2025-02-27 | — | — | US | disclosed |
| US-20240374603-A1 | PHARMACEUTICAL PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF | COHERENT BIOPHARMA (SUZHOU) LIMITED (CN) | 2024-11-14 | — | — | US | disclosed |
| CN-118475346-A | Pharmaceutical preparation, method for the production and use thereof | 同宜医药（苏州）有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-118401554-A | Antibodies against extracellular epitopes of the human TRPV6 channel and diagnostic and therapeutic uses thereof | 里尔大学 | 2024-07-26 | — | — | CN | disclosed |
| EP-4385498-A1 | PHARMACEUTICAL PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF | Coherent Biopharma (Suzhou), Limited (CN) | 2024-06-19 | — | — | EP | disclosed |
| CN-117717614-A | Nanometer diagnosis and treatment structure with visible light and near infrared fluorescence emission and application thereof | 上海交通大学 | 2024-03-19 | — | — | CN | disclosed |
| US-11884709-B2 | Peptides for the treatment of resorptive bone disease | UNIVERSITY OF NEW BRUNSWICK (CA) | 2024-01-30 | — | — | US | disclosed |
| WO-2023227517-A1 | FORMULATION OF API'S AND EXCIPIENT'S IN AN ICELL VIA HYDROPHOBIC ION PAIRING | DANMARKS TEKNISKE UNIVERSITET (DK) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023227518-A1 | POROUS EXPANDING BIOCOMPATIBLE SCAFFOLDS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2023-11-30 | — | — | WO | disclosed |
| EP-4282448-A1 | POROUS EXPANDING BIOCOMPATIBLE SCAFFOLDS | Danmarks Tekniske Universitet (DK) | 2023-11-29 | — | — | EP | disclosed |
| EP-4282435-A1 | FORMULATIONS OF ACTIVE PHARMACEUTICAL INGREDIENTS AND EXCIPIENTS IN ICELLS VIA HYDROPHOBIC ION PAIRING | Danmarks Tekniske Universitet (DK) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023036193-A1 | PHARMACEUTICAL PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF | 同宜医药（苏州）有限公司 | 2023-03-16 | — | — | WO | disclosed |
| CN-114748620-A | Nano-composite for treating malignant tumor and preparation method and application thereof | 宁波市第一医院 | 2022-07-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374603-A1 | PHARMACEUTICAL PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, NOTUM | TFPI 1653/4885NPY2R 2045/4885NPY4R 1750/4885 |
| US-20250064889-A1 | TRPV6 INHIBITORS AND COMBINATION THERAPIES FOR TREATING CANCERS | TRPV6, TRPM6, TRPV1 | TFPI 839/4885NPY2R 1558/4885NPY4R 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.